These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37717927)

  • 41. Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting Taxanes in Perspective.
    Sachdev JC; Jahanzeb M
    Clin Breast Cancer; 2016 Apr; 16(2):73-81. PubMed ID: 26603443
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04).
    Futamura M; Ishihara K; Nagao Y; Ogiso A; Niwa Y; Nakada T; Kawaguchi Y; Ikawa A; Kumazawa I; Mori R; Kitazawa M; Hosono Y; Kuno M; Kawajiri M; Nakakami A; Takeuchi M; Morikawa A; Tokumaru Y; Katagiri Y; Asano Y; Mushika Y; Shimokawa T; Matsuhasih N
    Breast Cancer; 2023 Mar; 30(2):293-301. PubMed ID: 36609911
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Feasibility Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (150 mg/m
    Kojima Y; Kawamoto H; Nishikawa T; Hayami R; Shimo A; Haku E; Akiyama K; Tsugawa K
    Clin Breast Cancer; 2018 Oct; 18(5):374-379. PubMed ID: 29452759
    [TBL] [Abstract][Full Text] [Related]  

  • 44. De-escalated neoadjuvant therapy with nanoparticle albumin-bound paclitaxel and trastuzumab for low-risk pure HER2 breast cancer.
    Tanaka S; Matsunami N; Morishima H; Oda N; Takashima T; Noda S; Kashiwagi S; Tauchi Y; Asano Y; Kimura K; Fujioka H; Terasawa R; Kawaguchi K; Ikari A; Morimoto T; Michishita S; Kobayashi T; Sakane J; Nitta T; Sato N; Hokimoto N; Nishida Y; Iwamoto M
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1099-1104. PubMed ID: 30963212
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of taxanes in triple-negative breast cancer: literature review.
    Mustacchi G; De Laurentiis M
    Drug Des Devel Ther; 2015; 9():4303-18. PubMed ID: 26273192
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
    Sparano JA
    Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: a clinical review.
    Chirgwin J; Chua SL
    Breast; 2011 Oct; 20(5):394-406. PubMed ID: 21839635
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A phase II trial of dose-dense neoadjuvant gemcitabine, epirubicin, and albumin-bound paclitaxel with pegfilgrastim in the treatment of patients with locally advanced breast cancer.
    Yardley DA; Zubkus J; Daniel B; Inhorn R; Lane CM; Vazquez ER; Naot Y; Burris HA; Hainsworth JD
    Clin Breast Cancer; 2010 Oct; 10(5):367-72. PubMed ID: 20670921
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial.
    Tokunaga S; Takashima T; Kashiwagi S; Noda S; Kawajiri H; Tokumoto M; Nishimura S; Nishimori T; Ikeda K; Ogawa Y; Mizuyama Y; Sunami T; Tezuka K; Yamagata S; Ishikawa T; Kudoh S; Takada M; Hirakawa K; Ohira M
    Anticancer Res; 2019 Apr; 39(4):2053-2059. PubMed ID: 30952749
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer.
    Robidoux A; Buzdar AU; Quinaux E; Jacobs S; Rastogi P; Fourchotte V; Younan RJ; Pajon ER; Shalaby IA; Desai AM; Fehrenbacher L; Geyer CE; Mamounas EP; Wolmark N
    Clin Breast Cancer; 2010 Feb; 10(1):81-6. PubMed ID: 20133263
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
    Blum JL; Savin MA; Edelman G; Pippen JE; Robert NJ; Geister BV; Kirby RL; Clawson A; O'Shaughnessy JA
    Clin Breast Cancer; 2007 Dec; 7(11):850-6. PubMed ID: 18269774
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer.
    Estévez LG; Gradishar WJ
    Clin Cancer Res; 2004 May; 10(10):3249-61. PubMed ID: 15161677
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
    Zaheed M; Wilcken N; Willson ML; O'Connell DL; Goodwin A
    Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012873. PubMed ID: 30776132
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives.
    Schettini F; Giuliano M; De Placido S; Arpino G
    Cancer Treat Rev; 2016 Nov; 50():129-141. PubMed ID: 27665540
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer.
    Huang L; Chen S; Yao L; Liu G; Wu J; Shao Z
    Int J Nanomedicine; 2015; 10():1969-75. PubMed ID: 25792830
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: sensitivity analysis of randomized trials.
    Carbognin L; Sperduti I; Nortilli R; Brunelli M; Vicentini C; Pellini F; Pollini GP; Giannarelli D; Tortora G; Bria E
    Cancer Treat Rev; 2015 Mar; 41(3):262-70. PubMed ID: 25683304
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
    Tamura K; Inoue K; Masuda N; Takao S; Kashiwaba M; Tokuda Y; Iwata H; Yamamoto N; Aogi K; Saeki T; Nakayama T; Sato N; Toyama T; Ishida T; Arioka H; Saito M; Ohno S; Yamauchi H; Yamada K; Watanabe J; Ishiguro H; Fujiwara Y
    Cancer Sci; 2017 May; 108(5):987-994. PubMed ID: 28256066
    [TBL] [Abstract][Full Text] [Related]  

  • 58. NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto.
    Untch M; Jackisch C; Schneeweiss A; Schmatloch S; Aktas B; Denkert C; Schem C; Wiebringhaus H; Kümmel S; Warm M; Fasching PA; Just M; Hanusch C; Hackmann J; Blohmer JU; Rhiem K; Schmitt WD; Furlanetto J; Gerber B; Huober J; Nekljudova V; von Minckwitz G; Loibl S
    J Clin Oncol; 2019 Sep; 37(25):2226-2234. PubMed ID: 31082269
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy.
    Zelnak AB; Nikolinakos P; Srinivasiah J; Jonas W; Pippas A; Liu Y; Li X; Torres M; O'Regan RM;
    Clin Breast Cancer; 2015 Feb; 15(1):31-6. PubMed ID: 25065563
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem).
    McCarthy N; Boyle F; Zdenkowski N; Bull J; Leong E; Simpson A; Kannourakis G; Francis PA; Chirgwin J; Abdi E; Gebski V; Veillard AS; Zannino D; Wilcken N; Reaby L; Lindsay DF; Badger HD; Forbes JF;
    Breast; 2014 Apr; 23(2):142-51. PubMed ID: 24393617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.